Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
EPA guidance on treatment of negative symptoms in schizophrenia
by
Glenthøj, L. B.
, Nielsen, M. Ø.
, Dollfus, S.
, Sabé, M.
, Pezzella, P.
, Falkai, P.
, Gaebel, W.
, Nordentoft, M.
, Galderisi, S.
, Mucci, A.
, Kaiser, S.
, Bitter, I.
, Giordano, G. M.
in
Antidepressants
/ Antidepressive Agents - therapeutic use
/ Antipsychotic Agents - therapeutic use
/ Apathy
/ Clinical trials
/ EPA Guidance
/ Humans
/ Intervention
/ Meta-analysis
/ Negative symptoms
/ Practice Guidelines as Topic
/ Schizophrenia
/ Schizophrenia - drug therapy
/ Social research
/ treatment
2021
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
EPA guidance on treatment of negative symptoms in schizophrenia
by
Glenthøj, L. B.
, Nielsen, M. Ø.
, Dollfus, S.
, Sabé, M.
, Pezzella, P.
, Falkai, P.
, Gaebel, W.
, Nordentoft, M.
, Galderisi, S.
, Mucci, A.
, Kaiser, S.
, Bitter, I.
, Giordano, G. M.
in
Antidepressants
/ Antidepressive Agents - therapeutic use
/ Antipsychotic Agents - therapeutic use
/ Apathy
/ Clinical trials
/ EPA Guidance
/ Humans
/ Intervention
/ Meta-analysis
/ Negative symptoms
/ Practice Guidelines as Topic
/ Schizophrenia
/ Schizophrenia - drug therapy
/ Social research
/ treatment
2021
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
EPA guidance on treatment of negative symptoms in schizophrenia
by
Glenthøj, L. B.
, Nielsen, M. Ø.
, Dollfus, S.
, Sabé, M.
, Pezzella, P.
, Falkai, P.
, Gaebel, W.
, Nordentoft, M.
, Galderisi, S.
, Mucci, A.
, Kaiser, S.
, Bitter, I.
, Giordano, G. M.
in
Antidepressants
/ Antidepressive Agents - therapeutic use
/ Antipsychotic Agents - therapeutic use
/ Apathy
/ Clinical trials
/ EPA Guidance
/ Humans
/ Intervention
/ Meta-analysis
/ Negative symptoms
/ Practice Guidelines as Topic
/ Schizophrenia
/ Schizophrenia - drug therapy
/ Social research
/ treatment
2021
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
EPA guidance on treatment of negative symptoms in schizophrenia
Journal Article
EPA guidance on treatment of negative symptoms in schizophrenia
2021
Request Book From Autostore
and Choose the Collection Method
Overview
Negative symptoms of schizophrenia remain a major therapeutic challenge. The progress in the conceptualization and assessment is not yet fully reflected by treatment research. Nevertheless, there is a growing evidence base regarding the effects of biological and psychosocial interventions on negative symptoms. The importance of the distinction between primary and secondary negative symptoms for treatment selection might seem evident, but the currently available evidence remains limited. Good clinical practice is recommended for the treatment of secondary negative symptoms. Antipsychotic treatment should be optimized to avoid secondary negative symptoms due to side effects and due to positive symptoms. For most available interventions, further evidence is needed to formulate sound recommendations for primary, persistent, or predominant negative symptoms. However, based on currently available evidence recommendations for the treatment of undifferentiated negative symptoms (including both primary and secondary negative symptoms) are provided. Although it has proven difficult to formulate an evidence-based recommendation for the choice of an antipsychotic, a switch to a second-generation antipsychotic should be considered for patients who are treated with a first-generation antipsychotic. Antidepressant add-on to antipsychotic treatment is an option. Social skills training is recommended as well as cognitive remediation for patients who also show cognitive impairment. Exercise interventions also have shown promise. Finally, access to treatment and to psychosocial rehabilitation should be ensured for patients with negative symptoms. Overall, there is definitive progress in the field, but further research is clearly needed to develop specific treatments for negative symptoms.
Publisher
Cambridge University Press
This website uses cookies to ensure you get the best experience on our website.